Fibrinolytic therapy with tissue Plasminogen Activator (tPA) alone has been the standard for three decades, but due to its inefficacy and bleeding risk, tPA has been replaced by Primary Percutaneous Coronary Intervention (PPCI) as the treatment of choice for Acute Myocardial Infarction (AMI). By contrast to tPA mono-therapy, natural fibrinolysis uses a sequential combination of both biological activators, tPA and uPA, the native form of which is a proenzyme, prouPA. Both in vitro and in vivo, tPA and prouPA have complementary modes of action in fibrinolysis are synergistic when combined. In a published clinical trial, the patent study, 101 patients with AMI were treated with a 5 mg tPA bolus (5% of the standard monotherapy dose) followed by a modest infusion of prouPA. This sequential combination virtually doubled the coronary TIMI-3 infarct artery patency rate and reduced the mortality six-fold compared to the best results with tPA alone.
Fibrinolysis is the body’s natural defense that prevents physiological fibrin, needed for the repair of wear and tear vascular injuries, from building up and interfering with blood flow. Evidence that this system is functioning comes from the invariable presence of the fibrinolytic degradation product D-dimer in plasma (110-250 ng/ml). Therapy with tPA alone was believed to the biological pathway. However, this idea represented a fundamental misunderstanding of the biological system, which remains to be addressed . Ever since the FDA approved tPA for the treatment of AMI I 1987, it has been the activator choice. However, the body has two plasminogen activators, the second one being urokinase Plasminogen Activator (uPA), the native form of which is a proenzyme (prouPA) . Since both are required for an effective and safe fibrinolytic effect, the full potential of fibrinolytic therapy has never been evaluated.
The fibrinolytic clinical experience has been with tPA monotherapy almost exclusively and this has been sufficiently disappointing that fibrinolysis has become discredited. Primary Coronary Intervention (PPCI) is now the treatment of choice for AMI. For ischemic stroke, the tPA bleeding risk is higher and has obliged a one third tPA dose reduction which further diminished its efficacy. Even with this reduction, a 7% risk of intracranial hemorrhage remains . Due to this risk, reperfusion therapy must be delayed until a careful history and diagnostic studies have eliminated a bleeding risk or intracranial bleed. Because of these risks tPA remains “mired in controversy.” A more effective and safer fibrinolytic is, therefore, particularly urgently needed for ischemic stroke.Although PPCI is the uncontested treatment for AMI, it is handicapped by being a hospital procedure that is time-consuming, technically demanding, and costly. This limits the patient population that can be adequately served. In addition, optimal results are time-dependent. Reduction in AMI mortality is greatest when reperfusion is accomplished within 1-2 hours of the event . When it can be done within 70 minutes, the mortality was 1.2% . Similarly, in animal models the longer the coronary occlusion, the less salvageable myocardium remains . This places geographic limitations on treatment.Therefore, in not only for stroke but also for many AMI patients a better fibrinolytic is needed. Since these are among the commonest causes of morbidity and mortality worldwide, for the majority of patients only more effective and safer fibrinolysis can provide sufficiently timely reperfusion. The endogenous fibrinolytic system uses not one activator but two. Fibrinolysis is initiated by tPA when it is released from the vessel wall at the site of a fibrin clot. The tPA binds to the clot at its fibrin binding site on the D-domain of fibrin and activates plasminogen on the same domain fibrin [7,8]. The unbound tPA is then promptly cleared by its short (5 min) half-life and inhibited by its potent plasma inhibitor (PAI-1). Therefore, it does not contribute further to fibrinolysis. This serves the important physiological function of protecting hemostatic fibrin which has the same fibrin binding site and this is the main cause of bleeding by tPA. Therefore, the current practice of administering tPA by an intravenous infusion is a particularly unphysiological treatment.After fibrinolysis is initiated additional plasminogen binding sites are created which on the E-domain of fibrin . There are two of them [10,11]. Plasminogen on the first of these undergoes a conformational change which allows the intrinsic activity of prouPA to activate it . This is followed by reciprocal activation of prouPA to its enzymatic form (tcuPA) , and tcuPA then activates the remaining plasminogen completing fibrinolysis. This dual activator pathway is consistent with the modes of action of the activators since they are complementary  and have a synergistic lytic effect when combined . This mechanism was also corroborated the finding that tPA plasminogen activation was specifically promoted by the fibrin D-domain and that by prouPA only by the fibrin E-domain . This is also consistent with their complementary modes of action  and explains why both tPA and prouPA are required for effective lysis. It is also noteworthy that in this sequential combination tPA activates one plasminogen whereas uPA, which has two forms, activates two and is responsible for two-thirds of the fibrinolysis.The patent trial referred to in the abstract is the only published study in which the endogenous fibrinolytic paradigm of a sequential combination of the activators was tested clinically. In 101 AMI patients a mini bolus of tPA was administered to initiate fibrinolysis. In keeping with the findings that tPA was only responsible for this step, no additional tPA was given. This bolus was followed by a prouPA infusion of 90 minutes. This resulted in a complete infarct artery opening rate of 82% and an AMI mortality of 1%. . This compares with a 45% opening rate and a mortality of 6.3% in the best of the tPA studies (GUSTO) .Not long after this trial, the company that supported it (Farmitalia) was sold to Pharmacia, which abandoned all cardiovascular drug development. Therefore, the opportunity to do a second trial with this combination was lost. Nevertheless, the patent trial results stand as a positive proof of the concept and attest to the clinical potential obtainable when the natural fibrinolytic paradigm is used in fibrinolytic therapy.More recently, a single site mutant of prouPA has been developed which has the advantage of being five-fold more stable in plasma at therapeutic concentrations, making it much less likely to cause bleeding side effects. At the same time, it has all the other properties of native prouPA [19-24].
The administration of tPA alone for fibrinolysis was based on a misunderstanding and is analogous to trying to run a car on only its staring motor. tPA and prouPA have sequential and different modes of action which are complementary and gives them a synergistic lytic effect when combined. Only by using both activators can all the fibrin-bound plasminogens be activated at fibrin-specific, safe doses. This is the key to both fibrinolytic efficacy and minimization of bleeding side effects.
The author was fully responsible for this paper
Conflicts of Interest
The author is the Scientific Director of TSI, the company developing a uPA mutant for use in therapeutic fibrinolysis.